or Try an Advanced Search...

    Technical Analysis for SLXN - Silexion Therapeutics Ltd.

    Grade Last Price % Change Price Change
    F 0.58 -5.41% -0.03
    SLXN closed down 5.41 percent on Friday, September 27, 2024, on 27 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
    0 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Very Strong Down Down Down
    Historical SLXN trend table...
    Date Alert Name Type % Chg
    New 52 Week Closing Low Bearish 0.00%
    NR7 Range Contraction 0.00%
    Narrow Range Bar Range Contraction 0.00%
    Inside Day Range Contraction 0.00%
    Wide Bands Range Expansion 0.00%
    Oversold Stochastic Weakness 0.00%
    New 52 Week Closing Low Bearish -5.41%
    Narrow Range Bar Range Contraction -5.41%
    Wide Bands Range Expansion -5.41%
    Oversold Stochastic Weakness -5.41%
    Older End-of-Day Signals for SLXN ...

       Recent Intraday Alerts

    Alert Time
    Possible NR7 1 day ago
    Possible Inside Day 1 day ago
    Down 5% 1 day ago
    Down 3% 1 day ago
    Down 2 % 1 day ago
    View Earlier Intraday Alerts

    Free Daily (Stock) Chart Reading

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Read My Charts!
    Configure default chart indicators
    SLXN Chart by TradingView
    Basic chart:

    Profile

    Silexion Therapeutics is a pioneering clinical stage, oncology-focused biotechnology company dedicated to the development of innovative treatments for unsatisfactorily treated solid tumor cancers which have the mutated KRAS oncogene, generally considered to be the most common oncogenic gene driver in human cancers. The company conducted a Phase 2a clinical trial in its first-generation product which showed a positive trend in comparison to the control of chemotherapy alone. Silexion is committed to pushing the boundaries of therapeutic advancements in the field of oncology, and further developing its lead product candidate for locally advanced pancreatic cancer.
    Classification
    Sector: Financial Services
    Industry: Shell Companies
    Keywords: Biotechnology Cancer Oncology Chemotherapy Pancreatic Cancer Oncogenes Solid Tumor Cancers Human Cancers Ras Gtpase Oncogene Locally Advanced Pancreatic Cancer Oncology Focused Biotechnology

    Is SLXN a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Sep 24 Silexion Therapeutics Announces Significant New Data from Phase 2 Trial of LODER™ in Non-Resectable Pancreatic Cancer
    Sep 11 Why Dave & Buster's Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket
    Sep 9 PESG Releases Report on Silexion Therapeutics: Pioneering RNAi Technology in the Fight Against KRAS-Driven Cancers
    Sep 3 Silexion Therapeutics to Present at the H.C. Wainright 26th Annual Global Investment Conference
    Aug 15 Silexion Therapeutics Ltd. and Moringa Acquisition Corp Announce Closing of their Business Combination
    See more SLXN news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 13.5576
    52 Week Low 0.5508
    Average Volume 1,594,149
    200-Day Moving Average 9.52
    50-Day Moving Average 5.35
    20-Day Moving Average 0.93
    10-Day Moving Average 0.77
    Average True Range 0.34
    RSI (14) 20.63
    ADX 51.91
    +DI 11.16
    -DI 40.95
    Chandelier Exit (Long, 3 ATRs) 0.67
    Chandelier Exit (Short, 3 ATRs) 1.58
    Upper Bollinger Bands 1.38
    Lower Bollinger Band 0.48
    Percent B (%b) 0.11
    BandWidth 96.37
    MACD Line -1.13
    MACD Signal Line -1.43
    MACD Histogram 0.2917
    Fundamentals Value
    Market Cap 2.24 Million
    Num Shares 3.87 Million
    EPS 0.11
    Price-to-Earnings (P/E) Ratio 5.27
    Price-to-Sales 71.53
    Price-to-Book 13.58
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 0.67
    Resistance 3 (R3) 0.68 0.65 0.66
    Resistance 2 (R2) 0.65 0.63 0.65 0.65
    Resistance 1 (R1) 0.62 0.62 0.61 0.61 0.65
    Pivot Point 0.59 0.59 0.59 0.59 0.59
    Support 1 (S1) 0.56 0.57 0.54 0.55 0.51
    Support 2 (S2) 0.53 0.55 0.53 0.51
    Support 3 (S3) 0.49 0.53 0.50
    Support 4 (S4) 0.49